This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Nektar Therapeutics Inc (NKTR)

NASDAQ: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) -162.01M -171.86M -133.98M -37.94M
Operating Gains/Losses 0.00 0.00 0.00 0.00
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables 3.58M -867.00K 20.16M -20.30M
(Increase) Decrease in Inventories 4.82M -5.61M -5.39M -795.00K
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 6.20M -122.00K -3.38M 4.27M
(Decrease) Increase In Other Current Liabilities 2.80M 8.29M 4.38M -1.14M
(Increase) Decrease In Other Working Capital 73.19M -78.00K -30.73M -46.70M
Other Non-Cash Items 18.63M 7.93M 20.24M 30.17M
Net Cash From Continuing Operations -38.53M -129.76M -113.74M -55.87M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -38.53M -129.76M -113.74M -55.87M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -4.09M -10.58M -9.72M -31.46M
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments 0.00 0.00 0.00 0.00
Other Cash from Investing Activities 0.00 -19.62M 210.09M 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 49.91M 113.02M -111.95M 16.71M
Issuance of Debt 0.00 77.94M 0.00 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 8.21M 4.12M 224.31M 8.89M
Repayment of Long-Term Debt -2.99M -174.84M -1.98M -1.36M
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net -3.00M 119.59M 0.00 0.00
Net Cash From Financing Activities 2.22M 26.80M 222.34M 7.54M
Effect of Exchange Rate Changes 32.00K 60.00K 916.00K -219.00K
Net Change in Cash & Cash Equivalents 13.63M 10.12M -2.44M -31.84M
NKTR News

NKTR Nektar Therapeutics Inc

Analysts Ratings for NKTR

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 8 7 7 6
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
GET NKTR ANALYST REPORT

Brokerage Partners

NKTR Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs